International cooperation

• R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology.
• National Institute of Oncology, Hungary.
• Bialostockie Centrum Onkologii, Poland.
• Faculty of Medicine Siriraj Hospital Mahidol University, Bangkok.

The Institute aims to combine the efforts of oncology scientists and oncology practitioners from Lithuania and abroad in order to transfer the achievements of modern science into the clinics.

The National Cancer Institute and its international and national partners are engaged in advanced scientific research and are actively participating in various research domains and clinical trials conducted across the EU and the three EEA countries.

The international partner of the planned Competence Center – Oslo University Hospital (OUS) (www.ous-research.no/ous-ccc) is a foreign public legal entity that has had Comprehensive Cancer Center accreditation since 2017. In addition to healthcare services (more than 30,000 patients per year), OUS actively conducts scientific and experimental activities related to teaching and studies. The center has dedicated units for the commercialization and patenting of clinical research results, innovations, and scientific discoveries. The OUS Comprehensive Cancer Center aims to be a leading institution in Europe in the fight against cancer and cancer research and to serve as a center for competence development and transfer in the Nordic countries and Europe. The National Cancer Institute aspires to become a national Comprehensive Cancer Centre in Europe, following the example of its leading partner, Oslo University Hospital Comprehensive Cancer Centre, as established by the Consortium agreement from November 4, 2024.

Oslo University Hospital (https://www.oslo-universitetssykehus.no/oslo-university-hospital) and the National Cancer Institute (https://www.nvi.lt/en) have been closely collaborating in the fields of cancer diagnostics and therapy for over two decades. This cooperation encompasses not only the clinical departments of the institutions but also the scientific community. Since 2000, the group led by Prof. R. Rotomskis from the National Cancer Institute (NCI) has been conducting research on photodynamic tumour therapy in collaboration with the group led by Prof. J. Moan from Oslo University Hospital.

The National Cancer Institute, in accordance with a signed cooperation agreement, is currently participating (as a partner) in the implementation of the project “Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials” (PRIME-ROSE: https://www.matrix-fkb.no/en/prime-rose/project) within the Horizon Europe program. The main project coordinator is Oslo University Hospital. The PRIME-ROSE consortium aims to contribute to the "Mission Cancer" goal of optimizing treatment and improving the quality of life for over 3 million people by 2030. This consortium is based on bottom-up, physician-initiated innovative trials, similar to DRUP, providing broad access to precision medicine.

NCI is also participating in the "Network of Comprehensive Cancer Centres: Preparatory activities on the creation of National Comprehensive Cancer Centres and EU Networking (CraNe https://crane4health.eu)” project, which aims to establish a comprehensive cancer care center network (EU4Health program). The project's objectives include supporting and contributing to the final proposal for EU comprehensive cancer center standards through the CraNE Joint Actions. The CraNE Joint Actions are proposed to be funded in line with the model of the 5th European Cancer Plan, which states that the European Commission will establish an EU network connecting recognized national comprehensive cancer centers (NCCC) in each member state by 2025.